



LIANBIO

May 12, 2022

Disclaimer



The information herein contains statements about future expectations, plans and prospects for LianBio. All statements, other than statements of historical fact, included herein are forward-looking statements. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on LianBio's expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that may cause actual results to materially and adversely differ from those set forth in or implied by such forward-looking statements, including those risks and uncertainties that are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. LianBio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing LianBio's views as of any date subsequent to the date hereof.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and LianBio's own internal estimates and research. While LianBio believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third party sources. In addition, the third party information included in this presentation may involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while LianBio believes its own internal research is reliable, such research has not been verified by any independent source.

We are a global biopharmaceutical company dedicated to developing and commercializing paradigm-shifting medicines for patients with unmet medical needs in Greater China and other Asian markets



Bringing a pipeline of innovative therapies into the rapidly growing Greater China market



Established pharmaceutical in-licensing and development platform well positioned to capitalize on positive market trends and momentum



**Multiple near-term catalysts across a diverse late, mid and early-stage pipeline
Five clinically validated therapeutic candidates, nine in-licensed assets**



Experienced cross-border team with BD, alliance management, clinical development, regulatory and commercial expertise and track record



Key validating and differentiating partnerships with Pfizer and BridgeBio



Strong financial position with cash runway through mid 2024; cash balance of \$389.1 million as of March 31, 2022, which includes cash, cash equivalents, marketable securities and restricted cash

China is the Second Largest Pharmaceutical Market Today, with Innovation Agenda Propelling Strong Growth



Substantial unmet medical needs persist in China

- **Aging population > 1.4Bn, with a high disease burden** compared to developed countries¹
- **“Healthy China 2030” sets clear healthcare industry KPIs** from the government²
 - Improve key TA mortality rates, including CV and oncology
- Despite increased R&D activity, still **few China-originated first-in-class and best-in-class drugs approved**

Fostering innovation: continued momentum in policy and industry evolution




Comprehensive policies enacted to foster innovation

- China's five-year plan includes innovation priorities in TAs such as oncology and CV³
- Accelerated review and approval timelines of patented pharmaceuticals⁴



Expanding coverage and broadening access for innovative drugs

- Growth in basic medical insurance and commercial health insurance⁵
- NRDL now updated annually



Biotech ecosystem growth

- Improving capital markets and fund flows into Chinese biotech
- Increase in number of CROs, bioparks, biotechs, clinical trial centers




Healthcare infrastructure upgrades

- Upgrades to private and public hospitals and community health centers⁶
- Increasing number of healthcare professionals

1. GBD Global Healthdata Exchange 2019; 2. “Healthy China 2030” released by China State Council in July 2019; 3. “14th Five-Year Plan (2021-2025) and the Long-Range Objectives Through the Year 2035; 4. GBI; review time calculated as time interval between NDA submission date and approval date 5. MoHRSS; NRCMS; CIRC website; China Insurance Yearbook; Xrate 6.53 RMB/USD; 7. “Comprehensive Reform of Public Hospitals Notification of Subsidy Fund Budget” released by Ministry of Finance in Nov 2020

Potential U.S./EU Biotech In-licensing Opportunities for China¹



Early Innings:

- **< 10% of western innovative biotech medicines tapped for China**, and majority of in-licensed programs are concentrated in oncology
- Western biotechs seeking **strategic access to China as part of global enrollment acceleration** and commercial opportunity

1. CapitalIQ. assumes only one opportunity per company based on 10,794 total US/EU biotech companies as of July 2021. 2. Based on 857 cross-border deals from 2015-2020 per ChinaBio. 3. US-listed Chinese biotech companies include: Adagene, BeiGene, BeyondSpring, Burning Rock, Connect Biopharma, Genetron, Gracell Biotech, Hutchinson China Medical, I-Mab, Legend Biotech, and Zai Lab. Assumes pre-money IPO valuation for Adagene (\$738), Burning Rock (\$1,460), Connect Biopharma (\$758), Gracell Biotech (\$1,037), Genetron (\$1,158), I-Mab (\$695) and Legend Biotech (\$5,293) in 01-Jan-2019.



Differentiated Access to Innovation

- **Relationship with our founder** provides expanded BD opportunities, with unparalleled sourcing, access and clinical/scientific due diligence capabilities



- BD approach informed by
 - Deep scientific expertise
 - Region-specific development insights
 - Regulatory and commercial insights

Cross-Border Execution Platform

- Management team with deep experience and **proven track records across global and Chinese biopharma** companies
- Robust asset and alliance management with bilingual **U.S.-based team dedicated to alliance management**
- **Maximizing asset value** locally and globally through **bespoke development strategies**
 - Ability to facilitate potentially faster market entry through **bridging studies and accelerated pathways**
 - **Unique in-market indications** and combination strategies for **global-first expansion** studies

Commercial Model Provides Optionality

- **Integrated commercial infrastructure** built around **core therapeutic areas**, products and market segments
- **Optionality** to leverage commercial partnerships for **broad access** to select assets



- Commercialization strategies **beyond hospital channels** provide broadened opportunities

Pipeline of Innovative Medicines – 5 Clinically Validated Therapeutic Candidates



Global Development Status ¹							Clinically Validated	Partner
Therapeutic Area	Program	Indication	Phase 1	Phase 2	Phase 3/ Pivotal	Approved	Next step in China	
Cardiovascular	Mavacamten ²	Obstructive Hypertrophic Cardiomyopathy (oHCM)					China Phase 3 trial initiated January 2022	Bristol Myers Squibb
		Non-obstructive Hypertrophic Cardiomyopathy (nHCM)					Conduct registration enabling trial	
		Heart Failure with Preserved Ejection Fraction (HFpEF)					Conduct registration enabling trial	
Ophthalmology	TP-03	Demodex Blepharitis					Conduct China standalone Phase 3 trial	TARSUS
Oncology	NBTXR3 ³	Head and Neck Squamous Cell Carcinoma (HNSCC) ²					Join NANORAY-312 global Phase 3	NANOBIOTIX
		Solid Tumor IO Combinations					Join future global Phase 3 trial	
	Infigratinib ⁴	Second-line Cholangiocarcinoma w/ FGFR2 Fusions					Approved in Bo'ao region through early access program	QED therapeutics bridgebio
		First-line Cholangiocarcinoma w/ FGFR2 Fusions					Join ongoing PROOF-301 global Phase 3 trial	
		Gastric Cancer w/ FGFR2 Fusions and other FGFR-Driven Tumors ⁵					Complete China Phase 2a proof of concept trial	
	BBP-398	Advanced Solid Tumors					Conduct China Phase 1 monotherapy trial	navire bridgebio
		Non-Small Cell Lung Cancer (NSCLC)					Conduct China Phase 1 Osimertinib combo trial	
Inflammatory Disease	Omilancor	Ulcerative Colitis					Join potential future global Phase 3 trial	LANDOS BIOPHARMA
	NX-13	Ulcerative Colitis					Join potential future global Phase 3 trial	
	LYR-210	Chronic Rhinosinusitis (CRS)					Join ENLIGHTEN global Phase 3 trial	LYRA THECAPSULES
Respiratory	Sisunatovir	Respiratory Syncytial Virus (RSV)					Join potential future global Phase 3 trial	REVERAL Pfizer


1. The commercialization of each of our product candidates will require regulatory approval in the respective jurisdiction in which we intend to market such product candidate; however, obtaining and maintaining regulatory approval in one jurisdiction does not guarantee we will be successful in obtaining or maintaining regulatory approval of the product candidate in other jurisdictions that are material to the success of LianBio. 2. Mavacamten has received FDA approval in the US, which is not a part of our licensed territory, for the treatment of NYHA class II-III obstructive HCM. 3. NBTXR3 has received European market approval (CE mark) in the EU, which is not a part of our licensed territory, for the treatment of locally advanced soft tissue sarcoma. At present, we are not pursuing NBTXR3 in relation to this STS indication. 4. Infigratinib has received FDA approval in the US, which is not a part of our licensed territory, for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. 5. Ongoing Phase 2a gastric cancer and other FGFR-driven tumor standalone clinical trial in China. Separate investigator sponsored Phase 2 clinical trial of infigratinib in FGFR-driven tumors is ongoing in the United States.

Three Key Pillars for Patient Reach and Sustainable Growth





#1 Establish Commercial Footprint with Lead Assets

* All clinically validated*



#2 Leverage Infrastructure



#3 Expand Pipeline via Additional BD

- Deepen existing TA franchises
- Strategic multi-asset partnerships
- Combination opportunities

Oncology

Cardiovascular

Ophthalmology


Inflammatory Diseases

Respiratory



Current Portfolio Could Bring Innovative Medicines to ~16M Patients in China

Diversified pipeline assets address large patient populations across therapeutic areas, including those that have been historically underserved




Note: Figures represent 2020 estimates for indications potentially addressable by mavacamten, NBTXR3, BBP-398, infigratinib, omilancor, NX-13, LYR-210, and sisunatovir
*TP-03 depiction based on <10% current diagnosis rate assumption

LianBio has Rapidly Established a Platform to Serve as a Partner of Choice and Gateway to China



9 assets in-licensed, 3 clinical trials initiated, 7 INDs approved



Experienced Cross-Border Management Team Supported by a Highly Regarded Board of Directors



Management Team




Yizhe Wang, Ph.D.
Chief Executive Officer;
Board Member



Bristol Myers Squibb



Debra Yu, M.D.
President &
Chief Strategy Officer



McKinsey & Company

BAY CITY CAPITAL



Yi Larson
Chief Financial Officer



Pascal Qian
China General Manager



NOVARTIS



Michael Humphries
Chief Scientific Advisor



NOVARTIS



Brianne Jahn
Chief Business Officer



Nathan Chen
VP, Regulatory Affairs,
Pharmacovigilance and Project
Translational Development
Management



Bristol Myers Squibb



Levvy Lv, D. Eng
VP, Clinical Operations &
Translational Development



石藥集團有限公司
CSPC PHARMACEUTICAL GROUP LIMITED

Board of Directors



Konstantin Poukalov
Managing Director – Strategy,
Perceptive Advisors;
Executive Chairman, LianBio

Jefferies



Yizhe Wang, Ph.D.
Chief Executive Officer,
LianBio



Bristol Myers Squibb



Adam Stone
Chief Investment Officer,
Perceptive Advisors



Tassos Gianakakos
Former Chief Executive Officer,
MyoKardia



CODEXIS




MAXYGEN



Neil Kumar, Ph.D.
Chief Executive Officer,
BridgeBio



McKinsey & Company



Susan Silberman
Former Global President,
Emerging Markets, Pfizer



Wei Wei Chen
Former Vice President,
Chief Financial Officer,
Starbucks China



Select commercialization experience



Entresto™
(sacubitril/valsartan) tablets
24/26 mg • 49/51 mg • 97/103 mg

Plavix
Clopidogrel 75mg / 300mg

LIPITOR
atorvastatin calcium tablets

NORVASC
Amlodipin

Fraxiparine®

Avandia
rosiglitazone maleate

Betaloc® **Volibris**
Pradaxa ambrisentan



达伯舒®
信迪利单抗注射液
Sintilimab Injection

Verzenio®
abemaciclib

AFINITOR
(everolimus) tablets

Votrient™
200 mg

SUTENT
50 mg SUNITINIB
Zytostatikum

GEMZAR®
(gemcitabine)

Arzerra®
(ofatumumab)
Injection, for intravenous infusion
20 mg/mL

ALIMTA®
pemetrexed

爱优特®
咪唑替尼散



Xalatan®
latanoprost ophthalmic solution

Latanoprost

ZYPREXA
IntraMuscular
Olanzapine for Injection

Cialis®
(tadalafil) tablets
2.5 mg, 5 mg, 10 mg, 20 mg

Cymbalta®
duloxetine HCl

TIENAM®
amprolium sodium M20

Redoxon®

strattera™
atomoxetine HCl

Viread
tenofovir disoproxil fumarate
300mg tablets

EPIVIR
(lamivudine)
ORAL SOLUTION
10 mg/mL


VFEND®



olumiant®
(baricitinib) tablets
2 mg

taltz®
(ixekizumab) injection
80 mg/mL

Benlysta
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL



ADVAIR DISKUS®

Pulmicort®

SINGULAIR
10mg Tablets montelukast sodium

RELVAR ELLIPTA
fluticasone furoate/vilanterol

ANORO® ELLIPTA®
umeclidinium/vilanterol

Ventolin®
(albuterol sulfate)



Pipeline



Mavacamten for the Treatment of HCM and HFpEF


- Mavacamten is a **myosin inhibitor** that targets excessive contractility and impaired relaxation, myocardial energetics and compliance
- In development for the treatment of obstructive hypertrophic cardiomyopathy (**oHCM**), non-obstructive hypertrophic cardiomyopathy (**nHCM**) and heart failure with preserved ejection fraction (**HFpEF**)



China Opportunity

- 1.1M - 2.8M HCM** patients in China (67% oHCM / 33% nHCM)
- 3.7M HFpEF** patients, 10-20% of whom may potentially be addressed by mavacamten

Hypertrophic Cardiomyopathy



- Obstructive HCM (oHCM):** Characterized by dynamic LV outflow tract obstruction, in which the enlarged and diseased muscle blocks the flow of blood from the left ventricle to the rest of the body.
- Non-Obstructive HCM (nHCM):** No significant LV outflow tract obstruction (<30 mm Hg) at rest or with provocation. Driven by diastolic impairment due to the enlarged and stiffened heart muscle.

Clinical Activity Demonstrated in oHCM and nHCM

Clinical Data Summary

oHCM:

- Phase 3 EXPLORER-HCM trial demonstrated patients on treatment experienced statistically significant and clinically meaningful improvements
 - Primary endpoint: Improvement of symptoms and functional capacity (improvement in NYHA class and peak VO2)
 - Well-tolerated; safety results were comparable to placebo; only 2% drop out rate

nHCM:

- Phase 2 MAVERICK-HCM trial demonstrated physiologic benefit with dose dependent reduction in serum levels of NT proBNP, with potentially greater benefit in more severe disease

EXPLORER-HCM

Change from Baseline to Week 30			
	Mavacamten (n=123)	Placebo (n=128)	P-value
Primary Endpoint			
Composite functional, n (%)			
EITHER			
≥1.5 ml/kg/min increase in pVO2 with			
≥1 NYHA class improvement OR			
≥3.0 ml/kg/min increase in pVO2 with			
no worsening of NYHA class	45 (37%)	22 (17%)	0.0005
Secondary Endpoints			
Post-exercise LVOT peak gradient, mmHg, mean (SD)	-47 (40)	-10 (30)	<0.0001
Peak VO2, mL/kg/min, mean (SD)	1.4 (3.1)	-0.1 (3.0)	0.0006
NYHA improved ≥ 1 class, n (%)	80 (65%)	40 (31%)	<0.0001
KCCQ-CSS, mean (SD)	13.6 (14.4)	4.2 (13.7)	<0.0001
HCMSQ-SoB score, mean (SD)	-2.8 (2.7)	-0.9 (2.4)	<0.0001

Mavacamten Registration Pathway

Global Stage of Development


- **oHCM:** BMS received approval in the U.S. for the treatment of symptomatic NYHA Class II-III oHCM to improve functional capacity and symptoms
 - BMS presented additional supportive data April 2022:
 - Phase 3 VALOR-HCM study demonstrated mavacamten significantly reduced the need for septal reduction therapy (SRT) in patients with severely symptomatic oHCM who had been appropriate for SRT
 - Phase 3 EXPLORER-LTE study demonstrated sustained improvements in clinically meaningful CV outcomes at weeks 48 and 84
- **nHCM:** MyoKardia completed Phase 2 double-blind, placebo-controlled MAVERICK trial in symptomatic nHCM patients; BMS to initiate Phase 3 nHCM trial in 2022
- **HFpEF:** BMS initiated a Phase 2 trial of mavacamten in HFpEF in Feb 2021

China Development Plan

oHCM: P3 EXPLORER-CN China standalone trial ongoing; PK trial complete

- EXPLORER-CN design mimics EXPLORER-HCM, with some changes to account for **China-specific considerations**
 - Primary endpoint: Valsalva LVOTg
 - Secondary endpoints: resting LVOTg, NYHA and KCCQ
 - EXPLORER-CN initiated January 2022
- PK study complete, favorable tolerability & PK profile demonstrated
- Breakthrough Therapy Designation granted in China February 2022

EXPLORER-HCM




NBTXR3 for the Treatment of Solid Tumors


NBTXR3 is a radioenhancer designed to enhance the efficacy of radiotherapy without resulting in additional side effects on surrounding healthy tissue

Illustrative example of NBTXR3 activity

Radiotherapy (RT) Alone



NBTXR3 Activated by RT



*Dose enhancement determined by Monte Carlo simulation (CEA Saclay, France). In vitro data. Nanobiotix data.




China Opportunity

- **1.3M patients** receive radiation therapy annually as part of their cancer treatment¹
- **Up to 925K** patients across potential target indications
 - Locally advanced head and neck cancer: ~25K
 - Non-IO potential solid tumor indications: ~150K
 - IO combination potential solid tumor indications: ~750K

Broadly Applicable MOA: Clinical Proof of Concept Demonstrated Across Multiple Tumors and IO Combination

Nanobiotix Key Clinical Data

- **NBTXR3 + RT in soft tissue sarcoma**
 - CE mark approval in EU based on Phase 3 study showing 16.1% CRR w/ NBTXR3 +RT vs. 7.9% CRR w/ RT alone
- **P1 Expansion Study 102: NBTXR3 + RT in locally advanced head and neck cancer (n=41 evaluable patients)**
 - 85.4% ORR • mOS 18.1 months
 - 63.4% CRR • mPFS 10.6 months
- **P1 Study 1100: NBTXR3 + anti-PD-1+ RT in patients with HNSCC, lung metastases and liver metastases (n=16 evaluable patients)**
 - PD-1 naïve ORR: 80% target lesion
 - PD-1 prior non-responder ORR: 45% target lesion
 - Target lesion disease control rate: 94%



China Development Strategy

- LB plans to enroll patients in China as part of five potential future global Phase 3 trials, beginning with Nanobiotix's ongoing **Phase 3 NANORAY-312 clinical trial of NBTXR3 in locally advanced HNSCC**
- Additional trials to include IO combination approaches

TP-03 for the Treatment of Demodex Blepharitis (DB) and Meibomian Gland Disease (MGD)

TP-03 (lotilaner ophthalmic solution) is a GABA-Cl channel blocker in development for the treatment of Demodex blepharitis (DB), meibomian gland disease (MGD)



China Opportunity

- 43M DB patients
- 73M Demodex-driven MGD patients
 - ~50% of Demodex-driven MGD patients also have DB

Target Indications


Demodex Blepharitis (DB)

- Blepharitis is characterized by eye inflammation, burning, and tearing, and may be accompanied by a specific type of debris called “collarettes”
- A significant proportion of blepharitis cases are caused by eyelash follicle infestation by the Demodex parasite


Collarettes Are Pathognomonic Sign of Demodex Infestation

Collarettes Are Composed of Mite Waste Products and Eggs¹

- Regurgitated undigested material combined with epithelial cells, keratin, and mite eggs
- Contain digestive enzymes, which cause irritation



Meibomian Gland Disease (MGD)



- Common eye condition where the glands do not secrete enough oil or when the oil they secrete is of poor quality
- If left untreated, MGD can cause or exacerbate dry eye symptoms and eyelid inflammation
- Symptoms include dryness, burning, itching, stickiness/ crustiness, watering, light sensitivity, red eyes, foreign body sensation

All Pre-Specified Primary and Secondary Endpoints were Met in Tarsus's Saturn-1 and Saturn-2 Pivotal Trials

Tarsus completed two successful pivotal trials with consistency across endpoints

	Saturn-1 (Pivotal Phase 2b/3) N=421	Saturn-2 (Pivotal Phase 3) N=412	Combined Pivotal Data N=833
Primary Endpoint: Complete Collarette Cure	44% vs. 7% (p<0.0001)	56% vs. 13% (p<0.0001)	50% vs. 10%
Clinically Meaningful Collarette Cure (Grade 0 or 1)	81% vs. 23% (p<0.0001)	89% vs. 33% (p<0.0001)	85% vs 28%
Mite Eradication	68% vs. 18% (p<0.0001)	52% vs 14% (p<0.0001)	60% vs 16%
Lid Erythema Cure	19% vs. 7% (p<0.0001)	31% vs. 9% (p<0.0001)	25% vs 8%

Approximately 90% of patients experienced a clinically meaningful benefit with respect to collarettes, collarette grade improvement and mites per lash

Source: Tarsus Pharmaceuticals

Development and Regulatory Status

U.S.

- Tarsus has announced plans to submit NDA for TP-03 in DB to U.S. FDA in 2H 2022
- Phase 2a MGD trial to be initiated 1H 2022

China

- Conduct DB PK trial (N=12)
- Conduct DB **P3 China standalone trial** (N=150, 1:1 randomization)
 - Co-primary endpoints: collarette cure (0-2 collarettes per eyelid) at day 43, mite eradication at day 43
 - Secondary endpoints: composite cure of collarette and erythema (0-2 collarettes per eyelid and grade 0 erythema) at day 43
- Trials expected to be initiated 2H 2022

Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven cancers

- **QED received FDA approval of infigratinib for the treatment of patients with previously-treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement in May 2021**
- **Approval based on meaningful clinical activity demonstrated in Phase 2 trial in chemotherapy-refractory CCA patients with FGFR2 fusions**
 - BICR cORR of 23.1% (95% CI 15.6 – 32.2) in 2nd and later line patients
 - BICR cORR of 34.0% in true 2nd line patients
 - DOR of 5.0 mos (95% CI 3.7–9.3)
 - Infigratinib administered as third-and later-line treatment resulted in meaningful PFS and ORR benefit in patients with CCA and FGFR2 fusions ~7 mos
 - Current SoC (chemo) = ~3 mos PFS in 2L CCA

Phase 2 trial of infigratinib in chemotherapy-refractory CCA patients with FGFR2 fusions (n=108)

BICR- assessed objective response rate (ORR), % (95% CI)	23.1 (15.6–32.2)
≤1 previous line of therapy (n=50)	34.0
≥2 previous lines of therapy (n=58)	7.4
BICR-assessed best overall response	
Complete Response, n (%)	1 (1.1)
Partial Response, n (%)	24 (22)
Stable Disease, n (%)	66 (61)
Unconfirmed Complete or Partial Response	12 (11)
Progressive Disease, n (%)	11 (10)
Unknown, n (%)	6 (6)
BICR-assessed confirmed or unconfirmed response, % (95% CI)	34.3 (25.4 – 44.0)
BICR-assessed disease control rate, % (95% CI)	84.3 (76.0 – 90.6)
BICR-assessed median duration of response (IQR), months (95% CI)	5.0 (3.7 – 9.3)
BICR-assessed median PFS, months (95% CI)	7.3 (5.6 – 7.6)
Median OS, months (95% CI)	12.2 (10.7 –14.9)

BICR=blinded independent central review

QED's Development and Regulatory Status in the U.S.

- U.S. FDA approval in 2nd line CCA received May 2021
- Ongoing global Phase 3 PROOF-301 trial in 1st line CCA
- Ongoing global Phase 3 trial in urothelial carcinoma
- In Jan 2020 received Fast Track Designation for 1st line CCA


China Opportunity

- Estimated 72,000 patients diagnosed with CCA annually in China vs. 11,000 diagnosed in U.S.
- Estimated 480,000 patients diagnosed with GC annually in China vs. 26,350 diagnosed in U.S.


China Development Strategy and Regulatory Pathway

- LB will enroll patients in China as part of QED's ongoing global Phase 3 PROOF trial in first-line CCA
- LB initiated a Phase 2a proof of concept trial in China for FGFR2-amplified gastric cancer and other solid tumors with FGFR alterations

Cholangiocarcinoma Annual Incidence



Gastric Cancer Annual Incidence



Additional Pipeline Programs



BBP-398 (SHP2 inhibitor) for the treatment of MAPK pathway-driven solid tumors

- Differentiated profile with a shorter-half life, attractive PK/PD and clean tox
- SHP2 inhibitors have broad potential applications across a variety of tumors and are being developed as combination therapy



LYR-210 (implantable drug matrix) for the treatment of chronic rhinosinusitis (CRS) with 3.4M medically refractory patients in China

- Implantable drug matrix designed to consistently and locally elute mometasone furoate (steroid) to inflamed mucosal sinus tissue for up to six months with a single administration for surgically naïve patients
- Clinically validated with Ph2 statistically significant symptom improvement vs. control at 16, 20 and 24 weeks



Sisunatovir (fusion inhibitor) for the treatment of respiratory syncytial virus (RSV)

- No SAEs observed across ~200 patients treated to date; no cardiac toxicity observed to date, a key issue leading to failure of prior fusion inhibitors
- Potential applicability in high-risk patient segments including pediatric, elderly patients



Omilancor (LANCL2 agonist) for the treatment of IBD






- Oral, gut-restrictive mechanism (lack of systemic exposure) designed for a safe and convenient route of administration for treatment of moderate to severe IBD
- Rapidly growing IBD incident population in China

NX-13 (NLRX1 agonist) for the treatment of IBD

- In Ph1a safety study, NX-13 was shown to be well tolerated

Major Validating Milestones Highlight Strength of LianBio Business Development Engine



Partner	LianBio Partnership Date	Asset Milestone Post-Partnership
 Mavacamten 	Aug 2020	<ul style="list-style-type: none"> ✓ Oct 2020: MyoKardia <u>acquired by BMS for \$13.1B</u> ✓ Apr 2022: BMS received <u>U.S. FDA approval</u> of mavacamten for patients with symptomatic oHCM
 Sisunatovir 	Mar 2021	<ul style="list-style-type: none"> ✓ Apr 2022: Reviral enters agreement to be <u>acquired by Pfizer for up to \$525M</u>
  Infigratinib 	Oct 2019	<ul style="list-style-type: none"> ✓ May 2021: QED received <u>FDA approval</u> of infigratinib for patients with previously treated cholangiocarcinoma ✓ Mar 2021 & 2022: Helsinn Group and QED enter into and expand <u>infigratinib strategic collaboration</u>
 TP-03	Mar 2021	<ul style="list-style-type: none"> ✓ Jun 2021: <u>Positive pivotal results</u> in Tarsus's SATURN-1 trial (P2b/3 DB) – all primary and secondary endpoints met ✓ May 2022: <u>Positive pivotal results</u> in Tarsus's SATURN-2 trial (P3 DB) – all primary and secondary endpoints met



A differentiated strategic collaboration that provides sourcing, development and commercial optionality

- Provides LianBio and partners optionality to access **Pfizer's established commercial infrastructure** with a highly compliant, secure commercial engine
- At LianBio's election and Pfizer's ROFN, we can jointly develop and commercialize certain LianBio products
- Companies are also working together to **source, select and develop/register leading products for China**
 - Pfizer will contribute up to \$70M of non-dilutive capital for in-licensing and co-development activities



Preferential access to an innovative pipeline of more than 20 product development candidates

- BridgeBio is developing transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio is **advancing a broad, innovative pipeline** across rare disease, oncology, dermatology, and other indications
- LianBio already holds China rights to two of BridgeBio's oncology assets, **infigratinib** and **BBP-398**

Targeting 3 Additional Registrational Trial Initiations and Multiple Catalysts by End of 2022



Therapeutic Area	Program	Milestone / Catalyst	Anticipated Timing
Cardiovascular	Mavacamten	▪ Initiate Phase 3 EXPLORER-CN clinical trial in patients with oHCM	✓ Jan 2022
		▪ Mavacamten granted BTM for oHCM in China	✓ Feb 2022
		▪ <i>U.S. FDA approval for the treatment of symptomatic oHCM (BMS)</i>	✓ April 2022
		▪ Completion of PK trial in China, demonstrating favorable safety, tolerability and PK profile	✓ May 2022
		▪ Complete enrollment in Phase 3 EXPLORER-CN clinical trial in patients with oHCM	H2 2022
Ophthalmology	TP-03	▪ <i>Saturn-2 pivotal trial readout (Tarsus)</i>	✓ Apr 2022
		▪ Initiate Phase 3 clinical trial in patients with Demodex blepharitis in China	H2 2022
Oncology	NBTXR3	▪ <i>Global trial initiation of Phase 3 NANORAY-312 clinical trial in head and neck cancer (Nanobiotix)</i>	✓ Jan 2022
		▪ Initiate China portion of Phase 3 NANORAY-312 clinical trial in patients with head and neck cancer	H2 2022
	Infigratinib	▪ Initiate China portion of Phase 3 PROOF-301 clinical trial in patients with first line cholangiocarcinoma	H2 2022

We are a global biopharmaceutical company dedicated to developing and commercializing paradigm-shifting medicines for patients with unmet medical needs in Greater China and other Asian markets



Bringing a pipeline of innovative therapies into the rapidly growing Greater China market



Established pharmaceutical in-licensing and development platform well positioned to capitalize on positive market trends and momentum



**Multiple near-term catalysts across a diverse late, mid and early-stage pipeline
Five clinically validated therapeutic candidates, nine in-licensed assets**



Experienced cross-border team with BD, alliance management, clinical development, regulatory and commercial expertise and track record



Key validating and differentiating partnerships with Pfizer and BridgeBio



Strong financial position with cash runway through mid 2024; cash balance of \$389.1 million as of March 31, 2022, which includes cash, cash equivalents, marketable securities and restricted cash